Riix halkan haddii kani yahay war-saxaafadeedkaaga!

Daraasadda Koowaad ee Aadanaha ee Musharax cusub oo COVID-19 ah

Calaamadda Recbio
Written by Dmytro Makarov

Si wanaagsan loo dulqaatay oo astaan ​​badbaado oo wanaagsan, ma jiro SAE ama TEAE taasoo horseedaysa joojinta hore, ma jiraan calaamado muhiim ah oo aan caadi ahayn/natiijooyinka baaritaanka shaybaarka ee leh muhiimada caafimaad

Print Friendly, PDF & Email
  • 20μg ReCOV waxay keentay titer sare oo ah anti-SARS-CoV-2 ka-hortagga unugyada difaaca jirka, oo leh ugu yaraan heer la barbardhigi karo xogta la daabacay ee tallaallada mRNA, saadaalinta waxtarka rajo-gelinta ah ee ReCOV ee ka hortagga cudurrada ay keento SARS-COV-2
  • ReCOV waa lagu sii qiimayn doonaa waxtarka iyo badbaadada ee tijaabooyinka caafimaad ee waaweyn dhawaan

Jiangsu Recbio Technology Co., Ltd. Tijaabada ReCOV, jiil cusub, dib-u-habayn laba qaybood ka kooban oo COVID-19 ah. Guud ahaan, xogta hordhaca ah waxay muujisay in ReCOV si wanaagsan loo dulqaatay oo muujisay astaan ​​badbaado oo wanaagsan. 20μg ReCOV waxay keentay titer sare oo ah anti-SARS-CoV-2 ka-hortagga unugyada difaaca jirka, oo leh ugu yaraan heer la barbardhigi karo xogta la daabacay ee tallaalada mRNA, saadaalinta suurtagalnimada rajo-gelinta ReCOV ee ka hortagga cudurrada SARS-COV-2.

"Waxaa na dhiirigeliyay badbaadada horudhaca ah iyo astaanta difaaca jirka ee ReCOV ee tijaabadan FIH," ayuu yiri Dr. Liu Yong, Guddoomiyaha iyo Maareeyaha Guud. "Tallaallada kahortaga ah ayaa weli ah hababka ugu waxtarka badan ee looga hortago infekshanka SARS-CoV-2 laguna xakameeyo masiibada adduunka. Waxaan rajeyneynaa inaan bixino jiilka soo socda ee tallaalka COVID-19 oo leh suurtagalnimada badbaadada, waxtarka iyo helista, waxaanan u hormarin doonaa ReCOV daraasado caafimaad oo waaweyn dhawaan si loo qiimeeyo waxtarkeeda iyo badbaadadiisa."

Tijaabada FIH-ka ee socota waa daraasad aan kala sooc lahayn, laba-indho-indho la'aan ah, daraasad la xakameynayo placebo si loo qiimeeyo badbaadada, falcelinta falcelinta, iyo difaaca jirka ee 2 kor u kaca qiyaasaha ReCOV, marka la maamulo sida 2 irbado gudaha muruqa ah (oo leh 21 maalmood kala duwan) maadooyinka caafimaadka qaba. Maanta Recbio waxa ay ka warbixisay xogta qayb ka mid ah oo aan indho la'aan ah oo badbaadada, falcelinta falcelinta iyo difaaca jirka ee Kooxda 1 (dadka waaweyn ee da'da yar/ReCOV 20μg).

Kooxdani waxa ay diiwaangelisay 25 ka qaybgalayaal kuwaas oo ahaa 18 ilaa 55 sano jir. Tijaabada, SARS-Cov-2-dhexdhexaadinta antibody-ka celceliska celceliska titers-ka (GMTs) ayaa loo beddelay WHO/NIBSC unugga IU/mL marka la barbardhigo ka-hortagga titer-ka-hortagga unugyada iyo kuwa tallaallada kale ee aadka loo isticmaalo. Recbio wuxuu helay GMTs 1643.2 IU/mL si looga takhaluso unugyada difaaca jirka 14 maalmood ka dib laba qiyaasood oo ReCOV ah, iyadoo labadaba heerka seropositive (SPR) iyo heerka seroconversion (SCR) ay yihiin 100%, taasoo soo jeedinaysa waxtarka ReCOV ee ka hortagga SARS-COV-2 cudurada keena. SARS-CoV-2 ka-hortagga unugyada difaaca jirka waxaa sameeyay shaybaadhka dhexe ee daraasadda (360Biolabs). Sida laga soo xigtay daraasad dhowaan la daabacay ka hor1, GMT ee SARSCoV-2 ka-hortagga unugyada difaaca jirka waxay ahaayeen 1404.16 IU/ml iyo 928.75 IU/ml 14 maalmood ka dib laba qiyaasood oo tallaalka Moderna iyo BioNTech/Pfizer mRNA, siday u kala horreeyaan.

Waxaa xusid mudan, iyadoo lagu saleynayo balaasmaha bini'aadamka ee la isku daray ee bukaannada ka soo kabanaya, heerka caalamiga ah ee WHO (oo ay ku jiraan 20/136, oo ay bixiso Machadka Qaranka ee Heerarka Bayoolojiga iyo Xakamaynta [NIBSC]) ayaa si weyn loo isticmaalay si loo cabbiro farsamooyinka ogaanshaha ee kala duwan.

Dhanka kale, xogta difaaca unugyada unugyada ayaa muujisay in ReCOV ay u horseedi karto jawaabaha unugyada CD4 + T ee antigen-ka ee dadka da'da yar, taasoo ka tarjumaysa soosaarka IFN-γ iyo IL-2, isbeddel muuqda oo ku wajahan Th1 phenotype ayaa lagu arkay heerka ugu sarreeya ee cytokines Th1 ee lagu ogaaday Maalinta 36 (14 maalmood kadib tallaalka 2aad).

ReCOV guud ahaan si wanaagsan ayaa loogu dul-qaatay nabdoonaanta iyo astaanta dulqaadka. Inta badan dhacdooyinka xunxun waxay ahaayeen kuwo khafiif ah darnaanta. Ma jiro SAE ama SHAAH taasoo horseedaysa joojinta hore, ma jiraan calaamado muhiim ah oo aan caadi ahayn/natiijooyinka shaybaadhka ee leh macnaha bukaan-socodka.

Recbio waxa ay horumarisay saddex goobood oo teknoloji-goyn ah oo loogu talagalay horumarinta cusub ee adjuvant, injineernimada borotiinka iyo qiimeynta difaaca jirka. Iyada oo ay taageerayaan aaladahaan, Recbio waxay sii wadaysaa inay ogaato oo ay horumariso koox buuxda oo ah musharaxiinta tallaalka cusub, sida kuwa soo socda ee HPV, shingles iyo tallaalada hargabka.

Print Friendly, PDF & Email

War ku saabsan qoraaga

Dmytro Makarov

Leave a Comment